PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
23796861-1	2013	PURPOSE: To characterize epileptic spasms (ES) occurring after the age of two years in patients with tuberous sclerosis complex (TSC), particularly treatment response to vigabatrin (VGB), which is extremely effective for infantile spasms (IS) in TSC.	Vigabatrin	170-180	TSC complex subunit 1	Homo sapiens	129-132	
32563542-8	2020	Multicenter, prospective studies are ongoing to identify if presymptomatic treatment with vigabatrin in patients with TSC can improve outcomes, including autism.	Vigabatrin	90-100	TSC complex subunit 1	Homo sapiens	118-121	
29881807-2	2018	Epilepsy occurs in 80%-90% of affected individuals during their lifetime, and up to one-third of children with TSC will develop epileptic (infantile) spasms, for which vigabatrin has been shown to be particularly effective.	Vigabatrin	168-178	TSC complex subunit 1	Homo sapiens	111-114	
23796861-1	2013	PURPOSE: To characterize epileptic spasms (ES) occurring after the age of two years in patients with tuberous sclerosis complex (TSC), particularly treatment response to vigabatrin (VGB), which is extremely effective for infantile spasms (IS) in TSC.	Vigabatrin	170-180	TSC complex subunit 1	Homo sapiens	246-249	
18345974-7	2008	Vigabatrin has proved to be effective against infantile spasms due to TSC.	Vigabatrin	0-10	TSC complex subunit 1	Homo sapiens	70-73